CA3226268A1 - M6pr cell surface receptor binding compounds and conjugates - Google Patents
M6pr cell surface receptor binding compounds and conjugates Download PDFInfo
- Publication number
- CA3226268A1 CA3226268A1 CA3226268A CA3226268A CA3226268A1 CA 3226268 A1 CA3226268 A1 CA 3226268A1 CA 3226268 A CA3226268 A CA 3226268A CA 3226268 A CA3226268 A CA 3226268A CA 3226268 A1 CA3226268 A1 CA 3226268A1
- Authority
- CA
- Canada
- Prior art keywords
- compound
- optionally substituted
- conjugate
- formula
- linker
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/02—Acyclic radicals, not substituted by cyclic structures
- C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/18—Acyclic radicals, substituted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/20—Carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/20—Carbocyclic rings
- C07H15/203—Monocyclic carbocyclic rings other than cyclohexane rings; Bicyclic carbocyclic ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
- C07H17/02—Heterocyclic radicals containing only nitrogen as ring hetero atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Saccharide Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163221915P | 2021-07-14 | 2021-07-14 | |
| US63/221,915 | 2021-07-14 | ||
| PCT/US2022/037196 WO2023288015A1 (en) | 2021-07-14 | 2022-07-14 | M6pr cell surface receptor binding compounds and conjugates |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3226268A1 true CA3226268A1 (en) | 2023-01-19 |
Family
ID=82786881
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3226268A Pending CA3226268A1 (en) | 2021-07-14 | 2022-07-14 | M6pr cell surface receptor binding compounds and conjugates |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20240335544A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4370156A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024524613A (cg-RX-API-DMAC7.html) |
| CN (1) | CN117915956A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022310346A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3226268A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023288015A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2024524614A (ja) | 2021-07-14 | 2024-07-05 | ライシア セラピューティクス, インコーポレイテッド | Asgpr細胞表面受容体結合化合物及びコンジュゲート |
| EP4651904A1 (en) | 2023-01-18 | 2025-11-26 | Lycia Therapeutics, Inc. | Lysosomal targeting bifunctional molecules for degradation of autoantibodies |
| EP4651901A1 (en) | 2023-01-18 | 2025-11-26 | Lycia Therapeutics, Inc. | Cycling lysosomal targeting antibody conjugates |
| WO2024155748A1 (en) * | 2023-01-18 | 2024-07-25 | Lycia Therapeutics, Inc. | M6pr binding compounds and conjugates |
| WO2024182772A2 (en) * | 2023-03-02 | 2024-09-06 | Avilar Therapeutics, Inc. | Mannose 6-phosphate receptor binding compounds for the degradation of extracellular proteins |
| FR3149188A1 (fr) * | 2023-05-31 | 2024-12-06 | Nanomedsyn | Pro-ligands, conjugués comprenant lesdits pro-ligands et leurs utilisations pour des applications thérapeutiques |
| WO2025021155A1 (zh) * | 2023-07-25 | 2025-01-30 | 深圳湾实验室 | 一种多特异性结合蛋白及其应用 |
| WO2026015664A1 (en) | 2024-07-10 | 2026-01-15 | Lycia Therapeutics, Inc. | Cycling lysosomal targeting chimeras targeting immunoglobulin e (ige) |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2002368077B2 (en) | 2001-07-12 | 2010-03-04 | Jefferson Foote | Super humanized antibodies |
| PT1628987E (pt) * | 2003-05-20 | 2009-10-29 | Pharmaxis Pty Ltd | Compostos manose-6-fosfonato para o tratamento de doenças inflamatórias |
| TR201808537T4 (tr) | 2004-09-23 | 2018-07-23 | Genentech Inc | Sistein değiştirilmiş antikorlar ve konjugatlar. |
| HUE061339T2 (hu) | 2014-03-19 | 2023-06-28 | Genzyme Corp | Targetáló csoportok helyspecifikus glikotechnikai átalakítása |
| PL3204425T3 (pl) | 2014-10-09 | 2021-03-08 | Genzyme Corporation | Glikomodyfikowane koniugaty przeciwciał z lekami |
| FR3041345B1 (fr) * | 2015-09-18 | 2019-06-14 | Nanomedsyn | Composes polysaccharides multi-fonctionnalises et leur utilisation pour cibler le recepteur du mannose 6-phosphate cation-independant |
| BR112018069147A2 (pt) * | 2016-03-23 | 2019-01-22 | Fimbrion Therapeutics Inc | composto da fórmula iii, composição farmacêutica, método de inibição da função de fimh e método de tratamento de uma doença mediada por fimh |
| EP3301175A1 (en) * | 2016-09-30 | 2018-04-04 | Rijksuniversiteit Groningen | Means and methods for mobilizing hematopoietic stem cells (hscs) |
| EP3897747A4 (en) | 2018-12-19 | 2022-12-07 | The Board of Trustees of the Leland Stanford Junior University | BIFUNCTIONAL MOLECULES FOR LYSOSOMA TARGETING AND RELATED COMPOSITIONS AND METHODS |
| US20230051872A1 (en) | 2019-03-22 | 2023-02-16 | Reflexion Pharmaceuticals, Inc. | Multivalent D-Peptidic Compounds for Target Proteins |
| EP3941580A1 (en) | 2019-03-22 | 2022-01-26 | Reflexion Pharmaceuticals, Inc. | D-peptidic compounds for vegf |
| EP4087584A4 (en) * | 2020-01-10 | 2024-08-28 | Lycia Therapeutics, Inc. | Cell surface receptor binding compounds and conjugates |
| US20230226214A1 (en) * | 2020-06-24 | 2023-07-20 | Lycia Therapeutics, Inc. | Bifunctional bridging compositions for viral transduction |
| EP4171658A4 (en) * | 2020-06-24 | 2025-04-09 | Lycia Therapeutics, Inc. | Modified viral compositions for viral transduction |
-
2022
- 2022-07-14 CN CN202280060559.6A patent/CN117915956A/zh active Pending
- 2022-07-14 EP EP22750970.0A patent/EP4370156A1/en active Pending
- 2022-07-14 US US18/578,293 patent/US20240335544A1/en active Pending
- 2022-07-14 WO PCT/US2022/037196 patent/WO2023288015A1/en not_active Ceased
- 2022-07-14 AU AU2022310346A patent/AU2022310346A1/en active Pending
- 2022-07-14 CA CA3226268A patent/CA3226268A1/en active Pending
- 2022-07-14 JP JP2024501118A patent/JP2024524613A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2023288015A1 (en) | 2023-01-19 |
| AU2022310346A1 (en) | 2024-01-25 |
| US20240335544A1 (en) | 2024-10-10 |
| EP4370156A1 (en) | 2024-05-22 |
| CN117915956A (zh) | 2024-04-19 |
| JP2024524613A (ja) | 2024-07-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA3167272A1 (en) | Cell surface receptor binding compounds and conjugates | |
| CA3226269A1 (en) | Asgpr cell surface receptor binding compounds and conjugates | |
| US20240335544A1 (en) | M6pr cell surface receptor binding compounds and conjugates | |
| AU2017359043B2 (en) | Steroids and protein-conjugates thereof | |
| CN112004557B (zh) | 类固醇类化合物及其抗体偶联物 | |
| AU2018269568B2 (en) | Bis-octahydrophenanthrene carboxamides and protein conjugates thereof | |
| AU2024205046A1 (en) | Cyclodextrin protein drug conjugates | |
| CA3183184A1 (en) | Camptothecin analogs conjugated to a glutamine residue in a protein, and their use | |
| CA3080857A1 (en) | Hydrophilic linkers for antibody drug conjugates | |
| CA3198788A1 (en) | Camptothecine antibody-drug conjugates and methods of use thereof | |
| KR20170004005A (ko) | 아시알로당단백질 수용체의 표적화제로서 치환된-6,8-다이옥사바이사이클로[3.2.1]옥탄-2,3-다이올 화합물 | |
| KR20210106467A (ko) | 튜불리신 및 단백질-튜불리신 접합체 | |
| CA3185601A1 (en) | Tubulysins and protein-tubulysin conjugates | |
| WO2024155748A1 (en) | M6pr binding compounds and conjugates | |
| KR20240135631A (ko) | 베루카린 a 유도체 및 이의 항체 약물 접합체 | |
| TW202519267A (zh) | Siglec配體、接合物及其使用方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250520 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250520 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20260519 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20260519 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20260709 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT Effective date: 20260709 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20260709 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20260731 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT Effective date: 20260731 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20260731 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20260731 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20260731 Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260731 |